Novartis Pharmaceutical Corporation
Seattle Genetics, Inc.
Topic: Myelodysplastic Syndrome and Chronic Myelogenous Leukemia
These symposia areintended to improve care of patients with hematological malignancies by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussions of novel agents at various stages of clinical development will be given significant focus. These enduring online activity are designed to provide clinical decision-making strategies for integration of novel therapeutic options.
This series consists of 5 continuing education symposia.